Early intraretinal fluid volume dynamics after switching from aflibercept 2 mg to faricimab in diabetic macular oedema
Acta Ophthalmologica · 14.11.2026
DOI: 10.1111/aos.70270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Ophthalmologica, online erschienen am 14.11.2026. Verfasst von Heiko Stino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Medical University of Vienna, Vienna, Austria. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
To evaluate intraretinal fluid (IRF) volume dynamics after switching from aflibercept 2 mg to faricimab in eyes with diabetic macular oedema (DME), stratified by prior response to aflibercept.
Methods
This retrospective study at the Medical University of Vienna included patients with DME who were switched from aflibercept 2 mg to faricimab. IRF dynamics and central subfield thickness (CST) were assessed after two faricimab injections. Eyes were categorized as prior responders or non‐responders based on their anatomical response to the last aflibercept injection (≥20% CST reduction or CST ≤250 μm). Optical coherence tomography (OCT)–derived CST and quantitative IRF volumes were analysed at baseline and after two faricimab injections. Associations between CST and IRF changes were evaluated.
Results
Fifty‐eight eyes of 45 patients (mean age 65.3 ± 10 years) were included, with 56 eyes previously treated with aflibercept. After two faricimab injections (mean follow‐up 10.1 ± 2.2 weeks), CST and total IRF volume decreased significantly ( p < 0.0001). CST reduction was strongly associated with IRF reduction in the central millimetre (estimate 1.00 [0.73–1.28], p < 0.0001), but less so with total IRF volume (estimate 0.22 [0.17–0.28], p < 0.0001). Responders ( n = 28) showed greater CST reduction compared to non‐responders (−105.6 ± 123.9 μm vs. −27.3 ± 60.1 μm; p = 0.0003) and lower total IRF volume after treatment ( p = 0.029), with more consistent regional improvements. Non‐responders showed smaller but still significant IRF reductions.
Conclusions
Switching from aflibercept 2 mg to faricimab resulted in significant reductions in CST and IRF volumes after two injections with a more pronounced effect in previous responders. While CST closely reflected central changes, its weaker association with total IRF reduction indicates that quantitative fluid assessment may further refine evaluation of treatment response and retreatment decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.
- Institute of Medical Statistics, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Heiko Stino, Paul Widmann-Sedlnitzky, Irene Steiner, Kim Lien Huber, Katharina Kriechbaum, Stefan Sacu, Andreas Pollreisz
Zitieren
APA
Stino, H., Tippow, A., Widmann-Sedlnitzky, P., Steiner, I., Huber, K. L., Gerendas, B., Kriechbaum, K., Sacu, S., & Pollreisz, A. (2026). Early intraretinal fluid volume dynamics after switching from aflibercept 2 mg to faricimab in diabetic macular oedema. Acta Ophthalmologica. https://doi.org/10.1111/aos.70270
Vancouver
Stino H, Tippow A, Widmann-Sedlnitzky P, Steiner I, Huber KL, Gerendas B, et al. Early intraretinal fluid volume dynamics after switching from aflibercept 2 mg to faricimab in diabetic macular oedema. Acta Ophthalmologica. 2026. doi:10.1111/aos.70270
BibTeX
@article{Stino2026,
author = {Stino, Heiko and Tippow, Antonia and Widmann-Sedlnitzky, Paul and Steiner, Irene and Huber, Kim Lien and Gerendas, Bianca and Kriechbaum, Katharina and Sacu, Stefan and Pollreisz, Andreas},
title = {Early intraretinal fluid volume dynamics after switching from aflibercept 2 mg to faricimab in diabetic macular oedema},
journal = {Acta Ophthalmologica},
year = {2026},
doi = {10.1111/aos.70270}
}
EUVIMED